During the previous funding period, we utilized our in vitro and in vivo models of the multiple myeloma (MM) cell in the bone marrow (BM) milieu to demonstrate the molecular mechanisms whereby proteasome inhibitors target tumor cells, host tumor interactions, and the BM microenvironment to overcome conventional drug resistance. We then rapidly translated these laboratory findings to the clinic leading to the FDA approval of Bortezomib for relapsed refractory MM in 2003 and relapsed MM in 2005. Importantly, our correlative science studies of patient samples have identified genomic profiles of patients most likely to respond. Although Bortezomib represents a major advance, not all patients respond, those that respond relapse, and no patients are cured. This proposal will therefore focus on using oncogenomics to define mechanisms of Bortezomib resistance. We will then validate novel targeted therapies to overcome Bortezomib resistance for evaluation in derived clinical trials.. To achieve these goals, we will pursue the following Specific Aims: to define the molecular determinants of proteasome inhibitor resistance using high throughput RNAi screens interrogating the effects of silencing the """"""""druggable genome"""""""" in a proteasome inhibitor resistant MM cell line (Specific Aim 1);to define strategies to overcome proteasome inhibitor resistance using in vitro preclinical models (Specific Aim 2);and to conduct preclinical in vivo studies and clinical trials to enhance sensitivity or overcome resistance to proteasome inhibitors (Specific Aim 3). This new paradigm to overcome proteasome inhibitor resistance in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with other hematologic malignancies as well as solid tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ye, Shuai; Lawlor, Matthew A; Rivera-Reyes, Adrian et al. (2018) YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res 78:2705-2720
Hunter, Zachary R; Xu, Lian; Tsakmaklis, Nickolas et al. (2018) Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv 2:2937-2946
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Michallet, M; Chapuis-Cellier, C; Dejoie, T et al. (2018) Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 32:376-382
Ray, A; Das, D S; Song, Y et al. (2018) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia 32:843-846

Showing the most recent 10 out of 407 publications